Key Highlights

  • A one-time lonvo-z infusion reduced attacks by 87% versus placebo during the six-month efficacy evaluation period.
  • Mean monthly attack rate was 0.26 in the lonvo-z arm compared with 2.10 in the placebo arm.
  • Collaboration Revenue decreased by USD 6.6 million, and Research and Development expenses decreased by USD 11.4 million.
  • The company estimates its cash funds ongoing operating expenses and Capital Expenditure requirements at least into 2028.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) reported third quarter 2026 results in which collaboration revenue decreased by USD 6.6 million compared with the third quarter of 2025. EPS was negative USD 0.91.

The decrease in collaboration revenue was primarily due to reductions in revenue under the 2016 Regeneron Agreement and the ATTR Co/Co. Research and development expenses decreased by USD 11.4 million. Both changes compare the three months ended September 30, 2026 with the same period of 2025.

Lonvo-z Efficacy Data

For the six-month efficacy evaluation period, weeks 5 to 28, a one-time infusion of lonvo-z reduced attacks by 87% versus placebo, with a mean monthly attack rate of 0.26 in the lonvo-z arm compared with 2.10 in the placebo arm (p less than 0.0001).

All patients in the lonvo-z arm experienced attack-rate reductions from baseline compared with weeks 5 to 28, and reductions were observed in all evaluated subgroups. All patients who received lonvo-z at baseline or in crossover after week 28 remained free from long-term prophylaxis therapy as of the February 10, 2026 data cutoff.

In April 2026 the company reported positive topline data from the global Phase 3 HAELO clinical trial of lonvo-z in hereditary angioedema. In September 2026 the FDA accepted the BLA for lonvo-z and granted it Priority Review with a PDUFA target action date of March 10, 2027. Preparations are underway for a planned commercial launch of lonvo-z in the first quarter of 2027, if approved. The filing notes the risk that the FDA may not approve the BLA such that the company can launch lonvo-z in the United States.

Nex-z Program

The filing describes an action that followed a report of Grade 4 liver transaminase elevations and increased total bilirubin in a patient dosed with nex-z in the MAGNITUDE trial. The primary endpoints are the change from baseline in modified Neuropathy Impairment Score +7 at month 18 and serum TTR at day 29.

The mNIS+7 scale is a validated measure designed to assess polyneuropathy impairment, including muscle weakness, muscle stretch reflexes, sensory loss and autonomic impairment. Favorable trends indicating stability or improvement were observed in most patients with ATTRv-PN after a single dose of nex-z across multiple clinical and biomarker measures, including the Neuropathy Impairment Score, modified body mass index, the Norfolk Quality of Life-Diabetic Neuropathy questionnaire, neurofilament light chain and the polyneuropathy disability score.

Financing Statement

The company's forward-looking statements include estimates of expenses, future revenues, capital requirements and needs for additional financing, including its ability to fund ongoing operating expenses and capital expenditure requirements at least into 2028. Reported detail: Collaboration revenue decreased by USD 6.6 million, and research and development expenses decreased by USD 11.4 million. The company estimates its cash funds ongoing operating expenses and capital expenditure requirements at least into 2028.